- Home
- EFSC vs VRDN Comparison
EFSC vs VRDN Comparison
Compare EFSC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EFSC | VRDN |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | 1418 | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | EFSC | VRDN |
|---|---|---|
| Price | $65.84 | $17.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $66.33 | $35.46 |
| AVG Volume (30 Days) | 220.0K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $14.22 | $13.73 |
| Revenue Next Year | $3.77 | $279.00 |
| P/E Ratio | $11.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $51.18 | $13.18 |
| 52 Week High | $66.18 | $34.29 |
Technical Indicators
Market Signals| Indicator | EFSC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 69.45 | 57.28 |
| Support Level | $52.48 | $15.58 |
| Resistance Level | N/A | $18.05 |
| Average True Range (ATR) | 1.38 | 0.74 |
| MACD | 0.26 | 0.16 |
| Stochastic Oscillator | 84.02 | 71.53 |
Price Performance
Historical ComparisonAbout EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Its Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.